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INTRODUCTION 
Diabetes mellitus is a global health issue 
affecting children, adolescents, and adults. 
According to the World Health Organization, 
the number of people with diabetes has risen 
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ABSTRACT 
Background and aims: Dyslipidemia is one of the major factors implicated in the 
development of the vascular complications of diabetes. In this study, it was evaluated 
the association between serum lipids profile and Hemoglobin A1c (HbA1c) in type 2 
diabetes mellitus. 
Methods: In this cross-sectional study, the serum lipid profile and HbA1c was studied on 
562 Iranian patients who were older than 30 years and had type 2 diabetes identified from 
the diabetes and metabolic diseases clinic of endocrinology and metabolism research 
institute. A Multiple Linear Regression analysis was also done with the HbA1c as 
outcome variable and serum lipids profile as predictor variables; adjusted for potential 
confounders (age, sex, diabetes duration and Body Mass Index (BMI)). 
Results: In 1966, 6.34% of the national total population was over 60 years compared to 
mean age of the participants that was 61.6±10.4 years, with a range of 32 to 89 years. The 
results confirmed that the Triglyceride (TG) (β: 0.11, 95% CI: 0.000-0.004, P=0.01) and 
cholesterol (β: 0.13, 95% CI: 0.000-0.009, P=0.04) were correlated with the HbA1c value 
but there were no significant association between HDL and LDL. 
Conclusion: This study demonstrated that in persons with type 2 Diabetes Mellitus 
(DM), HbA1c value is a good predictor of lipid profile. Therefore, lipid profiling for all 
persons with type 2 DM should be a routine test. 
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from 108 million in 1980 to 422 million in 
2014.
1
 The global prevalence of diabetes 
among adults over 18 years of age has risen 
from 4.7% in 1980 to 8.5% in 2014.
2
 
Dyslipidemia is a major systemic disorder 
and one of the important risk factors for 
cardiovascular disease. According to Adult 
Treatment Panel (ATP) III Guidelines  
At-A-Glance dyslipidemia is elevation of 
plasma cholesterol, TG, or both, or a low 
high-density lipoprotein level that contributes 
to the development of atherosclerosis.
3
 Many 
of reason cause elevated TG in patient with 
DM type 2; one reason is the enzyme that 
transport of free fatty acid cross the plasma 
membrane is Hormone Sensivit Lipse (HSL). 
Insulin inhabit HSL, insulin resistant in 
patient with uncontrolled type 2 DM cause 
activation HSL and increase fatty acid and 
transport free fatty acid from adipose tissue 
to liver and produced Very Low-Density 
Lipoprotein (VLDL) and increase TG.
4
 
Dyslipidemia is a powerful risk factor 
for coronary heart disease.
3
 Although DM 
and dyslipidemia are two separate risk 
factors for atherosclerosis, the results of 
many studies on patients with type 2 DM 
show that diabetes and dyslipidemia have 
a whole range of pathophysiological 
overlaps and that these interactions 
accelerate the process of atherogenesis.
5,6
 
The purpose of control of dyslipidemia in 
diabetic patients is Low-Density 
Lipoprotein Cholesterol (LDL-C) with a 
target level of <80 mg/dL (2.0 mmol/L).
6
 
The role of hyperglycaemia in 
Cardiovascular Disease (CVD) is supported 
by a direct correlation between fasting blood 
glucose and cardiovascular events.
7,8
 
Impaired lipid metabolism resulting from 
uncontrolled hyperglycemia has been 
implicated in cardiovascular complications 
in diabetes patients. Published reports 
suggest that the type 2 diabetes are 
associated with plasma lipid and lipoprotein 
abnormalities.
9,10
 All of dyslipidemia 
features is associated with an increased risk 
of cardiovascular disease in diabetes 
patients.
11
 
Glycated (HbA1c), as a reflection of 
glycaemia, is an important indicator of 
glycemic control for the previous 3 
months.
12
 Previous studies have not 
conclusively demonstrated that HbA1c is an 
indicator for dyslipidemia and 
cardiovascular disease in type 2 diabetes 
patients.
8,13,14
 In this study, the purpose of 
the current study was to examine the 
association between serum lipids profile and 
HbA1c in type 2 diabetic patients in Tehran 
between January and April 2014. 
 
METHODS 
In this cross-sectional study, we evaluated 
the clinical characteristics of 562 Iranian 
diabetic patients (older than 30 years and 
had type 2 diabetes) who were admitted to 
the diabetes and metabolic diseases clinic of 
endocrinology and metabolism research 
institute in Tehran between January and 
April 2014, were enrolled in the study. 
Inclusion criteria were age greater than  
30 years, type 2 diabetes (controlled  
or uncontrolled and with or without 
complications) and diabetes duration more 
than 5 years. Patients were excluded from the 
study if they were pregnant, had severe and 
enduring mental health problems, were not 
primarily responsible for their own care and 
refused to participate in the study or were 
participating in another research study. 
A checklist was administered from 
patient records regarding demographic 
information (sex, age, BMI, ethnicity, marital 
status, and education), current diabetes 
treatment (use of oral hypoglycemic agents 
and insulin), the duration of diabetes, and the 
presence of diabetes complications. The 
outcomes were serum lipids profile (TG, 
Cholesterol, HDL, and LDL) and HbA1c, 
ascertained from clinical patient records. 
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The protocol of this study was reviewed 
and approved by the Tehran University of 
Medical Sciences Institutional Ethical 
Review Committee. Informed consent was 
obtained from all of the subjects prior to the 
examinations. 
The quantitative and qualitative data 
were described as mean (standard deviation) 
and frequency (percentage), respectively. 
Pearson correlation coefficients were 
calculated to estimate relations between 
serum lipids profile and HbA1c in type 2 
diabetic patients. In addition, a multiple 
linear regression analysis was also done with 
the HbA1c as outcome variable and serum 
lipids profile as predictor variables; adjusted 
for potential confounders (age, sex, diabetes 
duration and BMI). Stata software, version 
12 (Stata Corp, College Station, TX, USA) 
was used for all statistical analyses. 
 
RESULTS 
Of 600 patients who were invited, 562 
(93.7%) cases accepted to participate. The 
mean (SD) age of the participants was 61.62 
(10.49) years, with a range of 32 to 89 years. 
Of 562 subjects, 232 (41.3%) were male. The 
mean (SD) duration of the illness was 12.82 
(6.61) years and the mean (SD) BMI of the 
participants was 27.85 (4.38) kg/m
2
, with a 
range of 18.1 to 47.4 kg/m
2
. There are 264 
(47.0%) patients with no complications of 
diabetes. Also, the prevalence of retinopathy, 
neuropathy and nephropathy complications of 
diabetes was 28.1%, 17.4%, and 14.2%, 
respectively as shown in Table 1. 
 
Table 1: Description of the population and association with HbA1c level (n=562) 
Characteristic n(%) P 
Sex Male 232(41.28) 0.24 
Female 330(58.72) 
Marital status Single 17(3.02) 0.74 
Marriage 463(82.38) 
Widow 82(14.59) 
Education Less than high school 186(3.09) 0.02 
High school graduate 102(18.15) 
At least some college 161(28.65) 
College graduate or beyond 113(20.11) 
Age (years) 30-44 30(5.34) 0.65 
45-59 209(37.19) 
60-74 254(45.20) 
75-90 69(12.28) 
Diabetes duration (years) < 5 45(8.0) 0.04 
5-9 172(30.6) 
10-14 141(25.1) 
≥ 15 204(36.3) 
BMI Underweight 6(1.1) 0.64 
Normal or healthy weight 141(25.1) 
Overweight 257(45.7) 
Obese 158(28.1) 
Nephropathy Yes 482(85.77) 0.11 
No 80(14.23) 
Neuropathy Yes 464(82.56) 0.38 
No 98(17.44) 
Retinopathy Yes 403(71.71) 0.02 
No 159(29.29) 
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Glycosylated (HbA1c) level in 48%  
of patients was less equal 7.5%, 31.1% 
between 7.6-8.9% and the rest is more equal 
9.0% (Table 2). 
 
Table 2: Associations between serum lipids profile and HbA1c with Chi-squared test 
(unadjusted) 
HbA1c ≤ 7.5% 7.6-8.9% ≥ 9.0% P 
TG Low risk (<150 mg/dL) 173 98 57 0.01 
Borderline (150-199 mg/dL) 49 48 28 
High risk (≥200 mg/dL) 48 29 32 
Cholesterol Low risk (<200 mg/dL) 243 158 91 0.001 
Borderline (200-239 mg/dL) 20 13 13 
High risk (≥ 240 mg/dL) 7 4 13 
HDL Low risk (> 60 mg/dL) 222 16 9 0.89 
Borderline (35-45 mg/dL) 121 89 58 
High risk (<35 mg/dL) 34 20 18 
LDL Low risk (<130 mg/dL) 254 165 100 0.01 
Borderline (130-159 mg/dL) 11 7 7 
High risk (≥160 mg/dL) 3 2 7 
 
The TG (β: 0.11, 95% CI: 0.000-0.004, 
P=0.01) and cholesterol (β: 0.13, 95% CI:  
0.000-0.009, P=0.04) were correlated with the 
HbA1c value but there were no significant 
association between HDL and LDL in adjusted 
linear regression models as shown Table 3. 
 
Table 3: Associations between serum lipids profile and HbA1c in adjusted linear regression models 
HbA1c *Adjusted Beta coefficient (95 % CI) P 
TG 0.11(0.000 to 0.004) 0.01 
Cholesterol 0.13(0.000 to 0.009) 0.04 
HDL -0.055(-0.008 to 0.002) 0.19 
LDL 0.010(-0.005 to 0.006) 0.86 
*: Adjusted for age, sex, diabetes duration, BMI. 
 
Figures 1 indicate the Pearson correlation 
between serum lipids profile and HbA1c in 
type 2 diabetic patients and the relationship 
between cholesterol (r=0.162, P<0.001), TG 
(r=0.152, P<0.001) and LDL (r=0.117, 
P=0.006) levels with HbA1c was significant. 
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Figure 1: Pearson correlation between serum lipids profile and HbA1c in type 2 diabetic patients 
 
DISCUSSION 
In the present study, we have evaluated 
the serum lipids profile in in type 2 diabetes 
mellitus subjects and its correlation with 
HbA1c. The results of this study showed that 
the levels of HbA1c are not affected by 
patients’ gender, marital status, age and 
BMI, But the significant correlation between 
HbA1c and age is in agreement with earlier 
reports.
15,16
 In this study, the levels of HbA1c 
was significant correlation with level of 
education (P=0.02) and Diabetes duration 
(P=0.04). 
We also surveyed the correlation 
between HbA1c with the prevalence of 
retinopathy, neuropathy and nephropathy 
complications of diabetes. The results 
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showed that the prevalence of retinopathy 
was correlation with level of HbA1c. Morton 
and et al inspected the relationship amongst 
HDL and micro vascular (renal and retinal) 
infection in an accomplice of 11140 patients 
with type 2 diabetes. Amid postliminary, 
32% of the patients grew new or exacerbating 
miniaturized scale vascular malady, and 28% 
encountering a renal occasion and 6% a 
retinal occasion.
17
 
We also surveyed significant correlations 
between HbA1c and cholesterol, TC, LDL 
and HDL ratio. In various studies, HbA1c 
level was eminent as showing positive 
correlation with TC, LDL and TG in 
diabetic patients.
18-20
 Our study showed a 
significant correlations between HbA1c, 
cholesterol and TG in diabetic patients 
which is in agreement with the findings of 
several other investigators who reported 
significant correlations between HbA1c and 
lipid profiles and suggested the importance 
of good management of diabetes in 
controlling dyslipidemia.
21-23
 The similarly 
more grounded relationship of HbA1c than 
FBG with lipid profile is upheld by a prior 
study reporting higher connection 
coefficients for HbA1c than irregular 
glucose, for example, cholesterol, TG and 
LDL.
24
 We did not watch huge connections 
between HbA1c with HDL and LDL. Be that 
as it may, in some past studies, it was 
critical connections.
25,26
 
In the present study, we divided diabetic 
patients into 3 groups according to their 
HbA1c levels: Group 1: Good glycemic 
control (HbA1c≤7.5%); group 2: Poor 
glycemic control (7.5%≤HbA1c≤8.9%) and 
group 3: Worst glycemic control 
(HbA1c≥9%). Though there was no 
significant differences in HDL in 3 groups 
with regard to glycaemia control, alterations 
in other lipid parameters were statistically 
significant in three different groups. 
The diabetic patients with poor 
glycaemia control displayed a huge 
increment in cholesterol and TG and with no 
huge modification in HDL and LDL. Prior, 
it was seen that type 2 diabetic patients 
without CHD had the same HbA1c levels 
independent of sex while female patients 
with CHD had higher HbA1c than particular 
male controls.
27
 Diabetes presents an 
extraordinarily expanded danger of CHD 
occasions in both ladies and men.
28
 In any 
case, ladies with diabetes seem to have 
encountered with an expanded CHD 
mortality.
29
 Diabetic ladies might be liable 
to more unfriendly changes in coagulation, 
vascular capacity and CHD hazard variables 
than diabetic men.
30,31
 Note that diabetic 
patients kept on being at expanded danger of 
CHD if their HDL levels remain problematic 
regardless of effective diminishments of 
LDL with statin treatment.
32
 Be that as it 
may, vulnerability to CVD among type 2 
diabetic patients varies extraordinarily as per 
ethnicity and sex.
33
 
Seriousness of dyslipidemia increments 
in patients with higher HbA1c esteem. As 
hoisted HbA1c and dyslipidemia are 
autonomous danger components of 
entanglements of diabetes, diabetic patients 
with raised HbA1c and dyslipidemia can be 
considered as a high hazard bunch for 
inconveniences of diabetes. Enhancing 
glycemic control can significantly decrease 
the danger of cardiovascular occasions in 
diabetics.
34
 It has been assessed that 
lessening the HbA1c level by 0.2% could 
bring down the mortality by 10%.
35 
The present study confirms the TG and 
cholesterol were correlated with the HbA1c 
value, but there were no significant 
association between HDL and LDL. In 
conclusion, we demonstrated that in persons 
with type 2 DM, HbA1c value is a good 
predictor of lipid profile. Therefore, lipid 
profiling for all persons with type 2 DM 
should be a routine test. 
The benefits of current study are 
including: Significant volume of cases and 
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accuracy in choosing of cases. In other hand, 
this study is done on patients of referral clinic 
of Tehran University of Medical Sciences 
and these cases are representing the statistic 
society of diabetic patients of Tehran. 
 
CONCLUSION 
This study demonstrated that in persons 
with type 2 DM, HbA1c value is a good 
predictor of lipid profile. Therefore, lipid 
profiling for all persons with type 2 DM 
should be a routine test. 
For further studies, it is suggested to do 
these actions with analytic and interventional 
methods that give us this ability to control 
variables that are responsible for bias and 
find their real relation. 
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